Niagen Bioscience (NAGE) Insider Steven Rubin Buys 31,746 Shares

Insider Buying and Selling at Niagen Bioscience, Inc.

Steven Rubin bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026. The shares were acquired at a price of $3.42 each, reflecting a significant investment in the company. This transaction highlights a growing trend of insider buying at Niagen, as several other insiders also made similar purchases on the same day.

Collective Insider Activity

On June 24, 2026, several insiders at Niagen Bioscience made notable purchases. Along with Steven Rubin, Yu Wing Tak Wendy, Hamed Shahbazi, Kristin Patrick, Ann Cohen, Ng Wang Yu Gary, and Jaksch Frank Jr. each acquired 31,746 shares. This collective buying could suggest strong confidence in the company's future direction, emphasizing a unified belief in its potential.

How Niagen Bioscience, Inc. Stock Has Traded

Niagen Bioscience's stock is currently trading at $3.42, which is above its 52-week low of $2.87. The stock has seen a range between $2.87 and $10.52 over the past year, indicating volatility. The recent insider purchases may provide a boost in confidence among other investors, especially as the company prepares to report earnings on November 3, 2026.

What Niagen Bioscience, Inc. Does

Niagen Bioscience, Inc. focuses on healthy aging products, including dietary supplements and proprietary ingredient technologies. The company's flagship product, TRU NIAGEN, contains nicotinamide riboside, which supports cellular metabolism. The recent insider buying aligns with the company's mission to enhance health and wellness through innovative products.

What’s Next for Niagen?

As Niagen Bioscience approaches its next earnings report on November 3, 2026, investors will be keen to see how the company's strategies are reflected in its financial performance. The recent wave of insider buying could be a positive sign for potential growth and stability in the company as it navigates the consumer defensive sector.